An ethanolic extract of powdered B. laciniosa was fed at varying doses to male albino Wistar rats in the treatment groups by feeding needle for 28 days, during which time their sexual behaviour was monitored, and after which their reproductive glands were weighed and analysed.

Mount frequency – total number of mounts during the period of observation. Intromission latency – the time between introduction of the female to the occurrence of the first intromission (penetration).

Post-ejaculatory latency – the lag time between first intromission to the next within 30 mins. Mount latency – the time between introduction of the female to the occurrence of the first mount.

All the markers of sexual performance were improved in treated animals compared to the control group.

The treated rats showed a dose-dependent increase in mount frequency, and a reduction in mount latency, intromission latency, and post-ejaculatory latency. In other words, they “got down to it” with the receptive female sooner, and more often, than the control rats.

The B. laciniosa extract-treated animals demonstrated an increased body weight and increased weight of the sexual organs including the testis, prostate, seminal vesicles, and epididymis.

There was a statistically significant increase in fructose content and sperm count in the highest-dose treated group (fructose is a major source of energy for sperm).

A significant increase was observed in the serum LH and testosterone of the rats treated at higher doses, the testosterone levels in particular appearing to increase by approximately a factor of ten among the highest dose group.

Structure of berberine

Berberine’s varied positive effects on many metabolic outcomes make it particularly of interest in treating the modern obesity-related condition known as “metabolic disorder”. Unfortunately, bioavailability for this compound is low – estimated at less than 5% of the orally-administered dose – the compound itself being poorly soluble, and the gram-plus doses necessary for a physiologically-relevant effect cause major gastrointestinal side-effects.

Super-Berberine^TM
Super-Berberine^TM solves these problems in two ways.

Firstly, in Super-Berberine^TMthe berberine is complexed with cyclodextrins.
Cyclodextrins are sugar molecules bound into a ring- or doughnut-shape, which can be used to increase the solubility of other compounds by the formation of inclusion complexes. The insoluble compound is held in the hydrophobic cavity, and the cyclodextrin acts as a “carrier” molecule.

Berberin-cyclodextrin complexes are not only more soluble, and therefore more bioavailable, than plain berberine, but also sweeter and less bitter due to the natural sugary taste of cyclodextrins and because complexed molecules cannot fully interact with taste buds.

Dissolution profiles of berberine and berberine-beta-cyclodextrin inclusion complex (a) in simulated gastric fluid and (b) in simulated intestinal juice.

The improvements in solubility seen in the graphs above may be improved further by use of 2 hydroxypropyl-β-cyclodextrin (HPβCD) instead of the less-soluble β-cyclodextrin.

Secondly, in Super-Berberine^TMthe berberine-cyclodextrins are co-administered with the penetration-enhancer sodium caprate.

Structure of sodium caprate

Sodium caprate is an absorption promoter, increasing the oral bioavailability of poorly permeable compounds across the gut wall. Many bioavailability enhancers work by increasing cellular permeability, allowing greater transcellular movement (through the epithelial cells) by diffusion or active transport.
Sodium caprate dilates tight junctions (TJs) in the intestinal epithelium, increasing their permeability, facilitating paracellular transport (between the cells). Sodium caprate also inhibits the excretion pump function of P-glycoprotein, of which berberine is a substrate.
As a sodium salt of a medium chain fatty acid, sodium caprate is Generally Recognized As Safe (GRAS) as a food additive.

When sodium caprate is co-administered with berberine, intestinal absorption of berberine increases significantly, leading to bioavailability improvements of 1.5 to 2.3-fold.

• In in vitro experiments, berberine has a stronger effect on the phosphorylation of AMPK than AICAR.
• Berberine reduces bodyweight in test animals fed a high-fat diet, as well as improving triglycerides, total cholesterol, and glucose tolerance.
• Berberine induces an increase in muscle glucose uptake via AMPK, and inhibits glucose production in the liver.

Combining cyclodextrin-complexed berberine with sodium caprate results in a berberine product of never-before-seen potency: Super-Berberine^TM.

References and further reading:

Aungst BJ. Absorption Enhancers: Applications and Advances. AAPS J. 2011 Nov 22;14(1):10–8.

Chen Y, Wang Y, Zhang J, Sun C, Lopez A. Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol. 2011;2011:519371.

Zhang Y, Cui Y-L, Gao L-N, Jiang H-L. Effects of β-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. International Journal of Biological Macromolecules. 2013 Aug;59:363–71.

Lv X-Y, Li J, Zhang M, Wang C-M, Fan Z, Wang C-Y, et al. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS PharmSciTech. 2010 Mar;11(1):372–82.

Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliv Rev. 2009 Dec 17;61(15):1427–49.

Krug SM, Amasheh M, Dittmann I, Christoffel I, Fromm M, Amasheh S. Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells. Biomaterials. 2013 Jan;34(1):275–82.

Zhang M, Lv X, Li J, Meng Z, Wang Q, Chang W, et al. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol. 2012 Nov 5;363(1-2):122–30.